• As host to B. Riley’s Securities’ 2021 Vision Day, SRAX offers event content to Sequire community
• SRAX CEO states that B. Riley event is “perfect example of our growing Virtual Event Platform capabilities”
• Definitive agreement between SRAX-created BIGtoken, FPVD closes

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, concluded its role as the exclusive technology host for B. Riley Securities’ 2021 Vision Day (https://ibn.fm/D7R3c); sessions from the event are available exclusively to B. Riley clients and investors on the Sequire platform. The company also announced that its BIGtoken platform closed on its share exchange agreement with Force Protection Video Equipment Corporation (OTC: FPVD), making BIG a public company through the reverse merger transaction (https://ibn.fm/ir6ii). The prestigious B. Riley Vision Day event was held on the Sequire Virtual Events platform, thereby allowing the Sequire community privileged access to sessions and content. The daylong virtual investor conference included video presentations and fireside chats discussing the top stock picks from B. Riley’s award-winning equity research team. All the sessions are available exclusively to B. Riley clients and investors who register at BRiley.mysequire.com. “We were honored to have been selected by B. Riley Securities to host its 2021 Vision Day event, following our success with the LD Micro Main Event in December,” said SRAX founder and CEO Christopher Miglino. “This event is a perfect example of our growing Virtual Event Platform capabilities. We were pleased to work with the B. Riley team and contribute to another successful event. Other big news for SRAX is the closing of the previously announced share exchange transaction between SRAX-created BIGtoken and Force Protection Video Equipment Corporation (OTC: FPVD). Initially announced on Sept. 30, 2020, the definite agreement outlined plans for SRAX to receive 88.9% of the issued and outstanding shares of FPVD in exchange for 100% of the shares of BIGtoken. The agreement also noted that upon completion of the transaction, FPVD would be renamed BIGtoken with Lou Kerner appointed CEO (https://ibn.fm/Z2Sa3). “Lou has been working with data and internet startups his entire career,” said Miglino. “He has a detailed understanding of Blockchain and how it is applied to augment business applications. Blockchain will play a big part in the future of consumer identity and privacy, and we have a shared vision with Lou on what this will look like. Not only is Lou a technology expert, but his knowledge of the capital markets will be a significant asset to BIGtoken as the company is uplisted to a nationally listed exchange.” SRAX is currently focused on unlocking data and insights through its software-as-a-service (SaaS) platform, Sequire. Launched as a standalone platform in early 2020, Sequire now has more than 3 million investors and traders, with an estimated 91 publicly listed companies as subscribers. The explosion in growth is driven by Sequire’s extensive range of services and as companies have increasingly sought to adopt digital technology and the data generated from such mediums as a way of improving their engagement with customers and stakeholders alike. For more information about SRAX and Sequire, visit the companies’ websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Most recent tests show MustGrow’s patented biopesticide achieved 100% control over Aphanomyces within 24 hours
• Plant-based biopesticide uses natural defense mechanism found in mustard seed to control diseases, pests and weeds
• MustGrow hoping to provide valuable crop-protection tool for pulse-crop farmers

MustGrow Biologics (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) has announced that its plant-based biopesticide has achieved 100% control of root-rot disease in a recent round of laboratory tests (https://ibn.fm/WJo4p). MustGrow, an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, is focused on providing natural, science-based biological solutions to replace synthetic chemicals in the cultivation process. MustGrow’s safe and effective organic biopesticide is plant based; it uses a natural defense mechanism found in the mustard seed to control diseases, pests and weeds. In a recent round of tests, which were conducted by an independent third-party lab, MustGrow’s patented mustard-derived biopesticide achieved 100% control over Aphanomyces euteiches zoospores (Aphanomyces) within 24 hours and at economic application rates. “It is great to see MustGrow’s mustard plant-based biopesticide continue to perform, particularly with 100% disease control measured at exceptionally low application rates,” said MustGrow COO Colin Bletsky. “The level of control of hard-to-kill diseases we continue to achieve combined with the beneficial properties of our product for soil health provide a great opportunity for improved yields for farmers and a more robust food supply. I am very hopeful that we can potentially provide a valuable crop-protection tool for pulse crop farmers.” Aphanomyces is a soil-borne, root-rot disease that destroys peas, lentils and legume crops, commonly referred to as pulse crops. In infected fields, the disease can result in yield losses ranging from 10% to 100% complete destruction. The ability to control the disease using an organic, plant-based biopesticide could have a significant impact on the harvests of farmers seeking to eradicate the disease. For instance, in 2019 Canada produced 9.2 million tons of pulse crops, making it one of the world’s largest producers. One study reported that Aphanomyces caused $20 million in annual pulse crop losses in Canada and $100 million worldwide. Currently the only available treatments slow down the spread in an attempt to reduce the severity of the disease; no treatments exist that control the devastating root-rot plague. MustGrow’s plant-based biopesticide aims to change that. With the most recent lab results in, MustGrow is now looking forward to evaluating its proprietary product in larger-scale greenhouse and field tests. MustGrow’s biopesticide is applied to the soil before crops are planted. The greenhouse and field tests are a significant step forward in the progression and preparation of the product for commercial use and application. This agriculture biotech company, which is focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, appears poised to leverage the growing momentum favoring alternatives to synthetic chemicals. As global agriculture looks to move closer to sustainable ways of boosting yields and crop protection, MustGrow continues to position itself as an essential part of the food landscape of the future with its mustard plant-based biopesticide. For more information, visit the company’s website at www.MustGrow.ca. NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

• Customers seek out highly personalized buying experiences in 2020 and beyond.
• Companies looking at what it means to be customer centric, how to create long-lasting relationships.
• Highly personalized customer service has always been high priority for SHRG.

As a new year begins, direct-selling leaders are looking to the future and wondering what trends will stick following the COVID-19 pandemic. Industry experts predict that companies with a strong customer-centric focus will perform the best moving forward, a prediction that bodes well for Sharing Services Global Corporation (OTCQB: SHRG). Sharing Services is committed to elevating the convenience and value of doing business for both its growing customer base and dedicated distributors. “The organizations that will perform the best through this period and beyond will be those that maintain a strong customer-centric focus while dealing with the complexity, uncertainty and risk that cloud the business landscape,” reported a recent “Direct-Selling News” article (https://ibn.fm/dEGMv). “This means knowing the sources of risk and opportunity within the global customer base. It means finding new routes to reaching customers—increasingly, through channels that customers control. And it means focusing less on driving customer transactions for short-term gain, and more on fostering trust-based relationships over the long term.” With that in mind, many companies are looking closely at what it means to be customer centric and how to create long-lasting relationships rather than short-term transactions. The rise of using digital tools instead of in-person sales was a necessity during the pandemic, but a convenience that may just stick around. Customers are seeking out tools that personalize their experience online. Add to this the rise of a gig economy, and the direct sales industry is experiencing massive growth. These are all priorities — and areas of expertise — for Sharing Services. SHRG markets and distributes health and wellness products under the Elevacity brand through an independent sales force of distributors called Elepreneurs. The company is committed to elevating customers’ and distributors’ lives through products, services and training opportunities. Sharing Services’ opportunity features a complete virtual business, including a phone app, web system and automated free sampling program — all designed to make it easier than ever before for SHRG Elepreneurs to focus on consumers. Customer centrism begins at home, observes the “Direct-Selling News” article. It starts on the front line with the distributors. Once the home front understands the value proposition of the company, sharing that message becomes second nature. SHRG executives have long credited the company’s success to its Elepreneurs, who are on the frontlines of the company and who continue to generate 100% organic growth. Through these entrepreneurs’ dedication to providing personalized customer experiences, customer retention has increased and capturing new markets has been achievable. Sharing Services Global Corporation is a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct selling sector and other industries. The Sharing Services combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. Sharing Services has two primary divisions: Elevacity(R) Holdings LLC, the parent company of Elevacity U.S. LLC, a health and wellness products company, and Elepreneurs Holdings LLC, the parent company of wholly owned subsidiary Elepreneurs U.S. LLC, a sales and marketing company based on utilization of independent contractor distributors who sell the Elevacity product line. For more information, visit the company’s website at www.SHRGInc.com NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Brain cancer drug developer CNS Pharmaceuticals is celebrating recent news that the U.S. Food and Drug Administration (“FDA”) granted investigational new drug (“IND”) status to CNS Pharmaceuticals’ leading candidate for fighting glioblastomas
• Glioblastomas are a class of aggressive brain cancers with no known cure and a median life expectancy of 14 to 16 months following diagnosis
• The FDA’s decision to grant CNSP’s request for IND status clears the way for the company to begin human clinical trials within the next couple of months
• The company’s sublicensee partner, WPD Pharmaceuticals, will also prepare a first-ever Phase I trial for drug safety in children, planned later this year in Poland

During the last year the COVID-19 pandemic has occupied large headlines worldwide while small neuro-oncology biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) has been quietly building a newsworthy effort of its own to improve a select group of individuals’ lives, preparing to launch medical trials that could help end the unrelenting and ultimately fatal advance of glioblastoma brain cancers. CNSP acquired the worldwide exclusive licensing to its leading drug candidate Berubicin, an anthracycline that has demonstrated its potential in fighting off glioblastomas and a stand-out drug among other anthracyclines because of its apparent ability to effectively cross the blood-brain barrier and target central nervous system malignancies. In a January podcast interview, company CEO John Climaco showed his excitement at news the U.S. Food and Drug Administration (“FDA”) had granted Berubicin investigational new drug (“IND”) status, clearing the way for the company to start human clinical trials and to ship the experimental drug across state lines to clinical investigators. “This is the biggest news we’ve announced since our IPO back in November 2019,” Climaco said. “Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials today to three active clinical trials. … We have five employees at this company, so we are a tiny little shop. But we have an absolute powerhouse compound.” The podcast, co-hosted by Sid Vaidya and Eric Gershey, is available for on-demand listening at https://anchor.fm/c3chat. Berubicin’s “powerhouse” potential was demonstrated in an initial Phase 1 trial completed by another company well over a decade ago. Within the very limited pool of participants in the trial, 44 percent saw their disease stabilize or even begin to improve. One patient emerged cancer-free and as of the most recent medical assessment last year was still alive and still in remission 14 years after the Phase 1 trial — a remarkable exception to the rule that the vast majority of glioblastoma patients will be dead within 14 to 16 months of diagnosis. CNSP’s planned Phase 2 trials will use a much larger pool of 243 patients for its real-time comparison of Berubicin’s performance against the “standard of care” chemotherapy drug lomustine in side-by-side brackets that compare the 162 Berubicin users with 81 lomustine users. The trials will take place in about 60 research centers scattered across North America, Europe and the Asia-Pacific region to help deliver a diverse representation of individuals (https://ibn.fm/4sWQi). While the adult trials are taking place, CNSP’s sublicensee partner for testing will also be preparing a first-ever Phase I trial for drug safety in children who have glioblastomas and have already failed to see a significant turnaround with standard-of-care medications. The pediatric trial is slated to begin later in the year in Poland. For more information, visit the company’s website at www.CNSPharma.com NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Canada’s Clean Power Capital Corp., a holding company focused on investing in the renewable energy sector, recently increased its equity interest in California’s PowerTap Hydrogen Fueling Corp. from 90 percent to 94.5 percent
• PowerTap inked an agreement last month with the companies collectively comprising the Andretti Group, operated by auto racing legends Mario and Michael Andretti to situate and market PowerTap’s hydrogen fueling technology
• PowerTap followed up on the agreement by appointing Michael Andretti to the company board
• PowerTap recently announced the strategy behind its business model, focusing on profit motivations for the retail locations where the fueling stations will be located and PowerTap’s opportunities to expand without land lease expenses
• North America is undergoing a renewed interest in renewable energy sources under the administration of new U.S. President Joe Biden and Canada’s Prime Minister Justin Trudeau

PowerTap Hydrogen Fueling Corp., a majority-owned investee interest of investment issuer Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF), is stepping up its dedication to clean energy infrastructure through cost-effective hydrogen fuel IP, modular fuel station product design flexibility and a launch plan for building a fueling network across California and into the rest of the nation.

PowerTap recently announced the appointment of auto racing legend Michael Andretti to its board following its January agreement with the businesses collectively known as the Andretti Group to install its 1,250-kilogram hydrogen production and dispensing stations at certain Andretti properties and to further market the stations to Andretti’s deep network of outside oil companies, chain retailers, cardlock operators and independent fueling stations.

The Andretti Group family of companies includes more than 100 retail chain stores focused on fuel, convenience and food operations. It runs or supplies facilities under the Chevron, Texaco, Shell, 76, Circle K, Pacific Pride and CFN brands, among others, throughout California, Oregon and Washington, according to the news release (https://ibn.fm/GI9vP).

PowerTap and the Andretti Group released further details on Feb. 8 regarding their strategic business model for the fueling stations and the ways PowerTap and retailers will benefit from the operation. Key points include using sites where the retailer can provide PowerTap with the necessary land for its modular hydrogen production and dispensing units without the need for lease expense to PowerTap and the retailer generates a profit from fuel sales by traditional methods, while PowerTap installs and maintains the units.

While the retailer is able to benefit from new traffic and find a new use for under-utilized land, PowerTap is able to operate its units without land expenses and is able to offer its customers the amenities inherent in existing fuel retail sites, leveraging the expertise of the Andretti Group’s affiliates.

“This exciting win-win relationship between PowerTap and the Andretti Group along with their industry partners will accelerate the deployment of our proprietary patented hydrogen production and dispensing technology, and provide a particularly compelling revenue share model with mutual benefit for all partners,” Incoming PowerTap President Salim Rahemtulla stated in the company’s announcement (https://ibn.fm/FRjnR).

North America’s renewed commitment to pursue “clean energy” through sources such as hydrogen fuel, as demonstrated by new U.S. President Joe Biden’s executive orders driving the country toward a carbon pollution-free power sector by 2035 (https://ibn.fm/jAXDY), coupled with Canada’s recently announced hydrogen strategy for building a net-zero carbon emissions infrastructure within the next three decades (https://ibn.fm/fZDVN) and Prime Minister Justin Trudeau’s acknowledgement that the two countries are poised to become collaborative partners in the clean energy supply chain (https://ibn.fm/cbl43), are further cause for excitement at PowerTap and Clean Power Capital.

PowerTap’s hydrogen-based technology is already being utilized at some hydrogen stations located at private and public sites in California, Texas, Massachusetts and Maryland. Clean Power announced Feb. 8 that it has increased its investment in PowerTap from a 90 percent equity interest to 94.5 percent as the Andretti agreements continue to build momentum (https://ibn.fm/LFkpy).

Clean Power holds 10 investments in varied sectors but restructured its corporate investment policy last year to focus on renewable energy. The company successfully held nearly $120 million in investments during 2020.The consideration paid for the additional 4.5 percent of PowerTap this year consisted of an aggregate of 18 million common shares in the capital of the company at a value of $2.72 per consideration share. The vendors have an arms-length relationship to each other and none of them individually owns more than 10 percent of the company’s shares on a non-diluted basis.

Clean Power is listed on the Canadian Securities Exchange’s CSE Composite Index (R) and the CSE25 (TM) index, and the company announced in December that it has formed a strategic committee to examine the possibility of listing common shares on the NASDAQ exchange in the United States (https://ibn.fm/2f2Yl).

For more information, visit the company’s website at www.CleanPower.Capital.

NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• Grapefruit expands availability of patented Hourglass by Grapefruit(TM) product to Greater Los Angeles area
• Hourglass is manufactured only at Grapefruit’s Coachillin facility, available only through Grapefruit authorized retailers
• GPFT achieved robust growth in 2020, poised to continue momentum going forward as demand remains strong

Grapefruit USA (OTCQB: GPFT), a premier fully licensed California-based company, has announced that its patented Hourglass time-release THC+Cannabinoid infused topical delivery cream has been rolled out to additional licensed retail cannabis locations in the Greater Los Angeles area (https://ibn.fm/ZohgC). Hourglass is manufactured exclusively at Grapefruit’s Coachillin facility and available only through Grapefruit authorized retailers. The company has announced that it will provide retail outlet locations as they come online in February as it continues to rapidly expand the number of California retailers that will carry the breakout Hourglass topical cream in the retail market. One of the recent additions includes licensed retail cannabis locations in Greater Los Angeles, California. Since the end of last year, Hourglass has been available to the public at Apothecary420, a well-respected dispensary located in Sherman Oaks, a suburb of Los Angeles. The company appears focused on rapid expansion as it continues to strengthen its premier brand recognized for high-quality products. In a recent update, the company announced recent developments concerning its patented Hourglass time-release THC+Cannabinoid delivery cream, reporting steady growth in market capitalization trading volumes. GPFT’s market capitalization grew from $11,809,990 on July 27, 2020, when the first major Hourglass project was announced to $30,282,026 at close on Jan. 15, 2021. Trading volume swelled over the same period, reflecting a robust investors’ demand (https://ibn.fm/k5J5m). But the company will not stop there. GPFT believes it can significantly improve this performance by the end of this year as the company grows other divisions and Hourglass capitalizes on the rise in demand for these unique products. Managed by a team of experts with relevant experience and skills to succeed in the competitive marketplace, GPFT leverages cutting-edge science and technology to deliver patented, truly disruptive products transforming the way consumers use the products. For more information, visit the company’s website at www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT

• Bergen Neurology Consultants utilized BRSF’s devices to improve patient care
• Minimal training means more staff can administer, monitor the EEG; more appointments can be scheduled

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company focused on developing innovative and proprietary medical devices and software, has created two devices designed to disrupt the EEG market. The NeuroCap(TM) and NeuroEEG(TM) offer cost-effective, disposable substitutes that help improve patient’s access to neurological care. The company is also helping improve the quality of care and solutions that practices can offer their patients. An example of the impact of the device can be seen through Bergen Neurology Consultants, a premier provider of neurological care (https://ibn.fm/6BVN6). Bergen Neurology wanted to offer its patients ambulatory EEGs. The problem is that strict Medicare regulations required a routine EEG first. Bergen Neurology’s offices were not set up to provide the traditional in-office EEGs that would make the ambulatory ones “medically necessary” for the insurance companies. The company discovered an optimal solution in the NeuroCap and NeuroEEG. Through its wholly owned subsidiary, MemoryMD Inc., BRSF was able to help Bergen Neurology Consultants streamline its practice, recoup revenue and improve patient care. Because of their size and ease of use, the NeuroCap and NeuroEEG allowed Bergen Neurology to implement in-office EEGs within a week. One problem with traditional EEGs is that administering and monitoring requires an EEG technician. Within an hour, all of Bergen’s six medical assistants were trained in how to administer and monitor the BRSF EEG devices. Workers who typically are involved in patient scheduling and administrative duties were allocated to this vital task with minimal training. This meant that more staff could administer the in-office EEGs allowing the practice to schedule them more often. The time it also took to use the NeuroCap and NeuroEEG decreased from one hour to 40 minutes, allowing for more tests to be scheduled. In addition, the original problem of reimbursement from insurance companies was resolved. Brain Scientific is working hard to disrupt the EEG industry and provide solutions that make neurological care more accessible. The company’s work with Bergen Neurology is an example of how BRSF is establishing a new innovative norm for clinicians. For more information, visit the company’s website at www.BrainScientific.com. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• “Forbes” highlights TAAT’s journey, value as alternative to tobacco cigarettes for smokers aged 21+
• Among smokers aged 21+, most prefer smoking experience to vaping, are looking for nonaddictive alternatives
• TAAT is seeing a pattern of repeat customers, reorders from retailers
• Famed Reddit stock trader Keith Gill, identified as one of investors behind recent rise of GameStop, listed TAAT ticker symbols in his notebook, which was photographed in news article earlier this month

TAAT Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF), a company that is dedicated to giving smokers aged 21+ a nicotine-free and tobacco-free smoking experience, was featured in “Forbes” on Feb. 3, 2021 (https://ibn.fm/o50bD). The article profiles TAAT CEO Setti Coscarella and his professional background in the tobacco industry, as well as his vision for the company as it enters the USD$814 billion global tobacco industry. The “Forbes” article also discusses the value of TAAT as an alternative to tobacco cigarettes. “I worked with thousands of smokers to better understand the things they liked and the things they didn’t like about smoking, and why they might look for any series of alternative products,” said Coscarella. “The vast majority of smokers are looking for alternatives.” TAAT is providing those alternatives with its new line of tobacco-free cigarettes, which are known as TAAT and are offered in Original, Smooth, and Menthol varieties. By creating an enjoyable user experience closely emulating how it feels to smoke a tobacco cigarette, TAAT believes it offers smokers aged 21+ a far superior product to vaping, gums, patches and other tobacco-cigarette alternatives. TAAT is currently sold at retail in Ohio under executive leadership straight from the tobacco industry, including Coscarella himself. Coscarella recognizes the potential in something that delivers the experience of smoking tobacco — but without any actual tobacco. TAAT’s nicotine-free cigarettes provide a nonaddictive solution that seeks to replicate the taste, smell and feel of tobacco. The “Forbes” article also highlights how inspiration was found in the commercialization strategy of meat product analogues (e.g., Beyond Meat) and the company’s decision to market to meat eaters rather than vegetarians. Coscarella took note and followed suit, positioning TAAT as a tobacco category product for smokers aged 21+ who enjoy smoking but want the choice to leave nicotine behind. The base material of TAAT, called Beyond Tobacco, undergoes a patent-pending refinement technique to taste and smell similarly to actual tobacco, in addition to mimicking the crackling sound of burning, the physical sensations of inhaling and exhaling, and even forming ashes that can be “flicked” in a similar manner to tobacco ashes. No detail has been overlooked in creating an experience for smokers aged 21+ that is satisfying yet nonaddictive. The article in “Forbes” notes that Keith Gill, more commonly known by his Reddit handle DeepFuckingValue, had TAAT’s ticker symbols (CSE: TAAT, OTCQB: TOBAF) on his handwritten list, which was published in a separate article. Gill was identified as one of the investors behind the rise of GameStop. “It doesn’t matter how you slice the numbers. I could absolutely suck and still do tens of millions of dollars a year in sales,” said Coscarella in the “Forbes” article. “I’m not going to speak for Keith Gill, but if he’s looking at it the same way that I’d be looking at it, it kind of becomes a no-brainer.” If repeat purchases are an indication, then it is safe to say that the TAAT brand might just be poised to meet these expectations. Approximately 60% of retailers who have carried TAAT for three or more weeks have already reordered, with many placing orders for a greater quantity than the first. There has been a pattern of repeat customers who have requested the brand by name during the second month of retail availability in Ohio (https://ibn.fm/XVWIv). To learn more about this company, visit www.TAATGlobal.com or www.TAATGlobal.com/investor-relations. NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF

• Pressure BioSciences to acquire the assets of a global, eco-friendly agrochemical supplier for worldwide distribution into food production markets
• Assets include formulations, manufacturer relationships, trademarks and other IP, registrations, licenses, and access to distributors and end-users
• Assets are being acquired from a company that was selling improved, effective, organically-natural, “green” agrochemical products
• Company expects that this new agrochemical business will not just be operational in 2021, but will generate significant revenue by the end of this year
• Worldwide market for agrochemicals is soaring
• PBI’S Patented Ultra Shear Technology(TM) (“UST”) produces high-quality stable nanoemulsions that can make oil-based products, such as perticides and fertilizers, far more water soluble and effective

South Easton, MA, February , 2021 – Pressure BioSciences (OTCQB: PBIO) (“PBI” or the “Company”), a global leader in the development and sale of broadly enabling, pressure-based instruments to the life sciences and other fields, announced it has signed a letter of intent to purchase the assets of an internationally-based, eco-friendly agrochemical developer.  This developer was previously engaged in providing environmentally sustainable alternatives to synthetic pesticides and fertilizers for agricultural production worldwide. Mr. Richard T. Schumacher, President, and CEO of PBI said “Upon completion, this acquisition of assets will bring into PBI an established portfolio of respected brand names in the eco-friendly agrochemicals market, with unique proprietary formulations, advantageous manufacturer relationships, trademarks, intellectual property, registrations and licenses, and access to the distributor and end-customer relationships around the world. We expect these assets to be accretive, driving significant new revenues and profitability in 2021 and beyond” (https://ibn.fm/S51XK). As the demand for food production increases worldwide, environmental sustainability becomes a huge concern. This has paved the way for a new generation of environmental-friendly agrochemicals. Consequently, the worldwide market for Pesticides should reach $131B by 2023 (https://ibn.fm/GfkTf) and Fertilizers should reach $232B by 2025 (https://ibn.fm/GHX2J). The common challenge faced by Agrochemicals involves effective and increased absorption of oily (hydrophobic) active ingredients, required for increased availability within targeted plant species. Pressure BioSciences was recently awarded its first U.S. patent for its novel Ultra Shear Technology (“UST”) platform, a process that has the potential of increasing the long-term stability, safety, water-solubility, and bio-availabity of many products in the pharmaceutical, nutraceutical, cosmetics, food and beverage, and now agricultural markets. UST is a nano emulsification platform, which can make oils effectively soluble in water. This technique is expected to provide improved agrochemical dosing while reducing the quantities of expensive active ingredients required (saving the manufacturer significant money). The company has filed patents in U.S., Canada, Europe, and Asia. UST uniquely combines intense shear forces generated from ultra-high-pressure valve discharge, under controlled temperatures, to produce high-quality stable nanoemulsions. In addition to saving the manufacturer significant money during processing, UST can also significantly reduce foodborne pathogens, thus making the nanoemulsified product much safer. As mentioned, the UST technology platform has the potential to play a pivotal role in a number of commercial sectors, e.g.,nutraceuticals, cosmetics, pharmaceuticals, cannabis oil extracts, industrial lubricants, and now agriculture where macro and micro emulsions of oil and water are commonly used.. Scientific studies indicate that nanoemulsions offer improved absorption, higher bioavailability, greater stability, lower surfactant levels, and other advantages over larger emulsions (https://ibn.fm/gOInC). About Pressure BioSciences Inc. Pressure BioSciences is a global leader in the development and sale of innovative, pressure-based solutions for the life sciences market and other industries. The company’s products are based on the unique alternating pressure cycling technology (“PCT”). The company’s primary focus is on the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. For more information, visit the company’s website at www.PressureBioSciences.com. NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• The InsuraGuest Hospitality Liability coverage expansion provides more opportunities for claims to be transferred to the InsuraGuest carrier, resulting in a higher reduction of general liability claims
• The lower risk profile with the absorption of more claims through InsuraGuest could result in even lower premiums for hotel operators and vacation rental owners
• The vacation rental market size is estimated to rise to a value of $113.9 billion by 2027, as more people choose vacation rentals over hotels because they are often more private and affordable
• InsuraGuest’s proprietary platform can now be integrated with 82 different software programs for easier claims processing

InsuraGuest Technologies (TSX.V: ISGI) (OTCQB: ISGIF), a leading insurtech company that is leveraging its proprietary software platform and disrupted the insurance landscape, has announced that through its wholly owned United States subsidiary InsuraGuest, Inc., it has expanded Hospitality Liability coverages to include accidental medical incidents that occur anywhere on a hotel’s premises. In addition to the coverage already available for incidents within the guest’s room, this coverage expansion now protects the hotel from claims made by guests should an accident occur on another part of hotel property – like the pool, gym, or parking lot (https://ibn.fm/EIEtM). The majority of hotel operators file their accident or small property claims through their general liability policies. When doing this, the frequency of the claims can drive up the price of the premium. The higher the risk, the higher the general liability insurance prices will be. InsuraGuest changes this dynamic by absorbing the risk, potentially keeping the hotel operator’s general liability premiums untouched, resulting in lower expenses for property owners. Through the Hospitality Liability coverage, these small claims can be filed through the InsuraGuest policy, which is paid for by having the guests pay a nominal fee per night for the coverage. “This expansion of our Hospitality Liability coverage to include hotel protection for guest accidents on hotel premises further advances InsuraGuest’s mission to help hotels significantly lower their risks and reduce claims made to their GL policies,” InsuraGuest Technologies Chairman and CEO Douglas Anderson explained. The InsuraGuest coverage was designed to offer offers an additional layer of protection that can be used if a guest experiences an accident, property damage in the room, theft, or death and dismemberment while staying on the covered hotel property. The coverage offering is provided through a proprietary software platform that is specialized to deliver Hospitality Liability coverages to the member hotel or vacation rental. The expansion comes at a time when vacation rentals are becoming increasingly popular types of arrangements for those who travel. They are so popular that Grand View Research estimates that the market size for these rentals will be worth $113.9 billion by 2027, growing at a CAGR of 3.4% (https://ibn.fm/XM47h). The reason for the increase is that more people choose to stay in a rental that is more like home, provides privacy, and is more kid and pet friendly. This growth offers multiple opportunities to InsuraGuest, a company committed to harnessing the power of technology to reinvent the insurance industry. With a proprietary software platform that currently integrates with 82 different property management software systems in both hotels and vacation rentals, and delivers digital insurance to multiple sectors across various industries, the company aims to revolutionize the way insurance is delivered based on the idea that insurance should be bought and not sold. For more information, visit the company’s website at www.InsuraGuest.com. NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI